Cue Biopharma, Inc. SEC filings CUE
Cue Biopharma, Inc. has 552 filings in SEC EDGAR's recent list, going back to Jun 19, 2015. Its latest annual report, Form ARS, was filed on Mar 16, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 21, 2026 (regulation fd disclosure, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Aug 20, 2026 | — |
| CORRESP | Letter to the SEC | Aug 18, 2026 | — |
| UPLOAD | Letter from the SEC | Aug 17, 2026 | — |
| D | Filing | Jul 22, 2026 | — |
| EFFECT | Filing | Jul 1, 2026 | — |
| CORRESP | Letter to the SEC | Jun 29, 2026 | — |
| UPLOAD | Letter from the SEC | Jun 25, 2026 | — |
| EFFECT | Filing | Jun 17, 2026 | — |
| CORRESP | Letter to the SEC | Jun 15, 2026 | — |
| UPLOAD | Letter from the SEC | Jun 10, 2026 | — |
| D | Filing | May 14, 2026 | — |
| EFFECT | Filing | Mar 31, 2026 | — |
| CORRESP | Letter to the SEC | Mar 27, 2026 | — |
| UPLOAD | Letter from the SEC | Mar 23, 2026 | — |
| UPLOAD | Letter from the SEC | Dec 16, 2024 | — |
| CORRESP | Letter to the SEC | Dec 11, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 5, 2024 | — |
| EFFECT | Filing | May 26, 2023 | — |
| CORRESP | Letter to the SEC | May 24, 2023 | — |
| UPLOAD | Letter from the SEC | May 16, 2023 | — |
| EFFECT | Filing | Dec 14, 2022 | — |
| CORRESP | Letter to the SEC | Dec 12, 2022 | — |
| UPLOAD | Letter from the SEC | Dec 9, 2022 | — |
| D | Filing | Nov 21, 2022 | — |
| EFFECT | Filing | May 21, 2021 | — |
| POSASR | Filing | Mar 9, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 31, 2019 | — |
| CORRESP | Letter to the SEC | Jul 9, 2019 | — |
| UPLOAD | Letter from the SEC | Jul 3, 2019 | — |
| CT ORDER | Filing | Feb 19, 2019 | — |
| EFFECT | Filing | Jul 19, 2018 | — |
| CORRESP | Letter to the SEC | Jul 17, 2018 | — |
| CORRESP | Letter to the SEC | Jul 13, 2018 | — |
| UPLOAD | Letter from the SEC | Jul 3, 2018 | — |
| CERT | Filing | Dec 18, 2017 | — |
| CT ORDER | Filing | Dec 15, 2017 | — |
| EFFECT | Filing | Dec 14, 2017 | — |
| 8-A12B | Filing | Dec 13, 2017 | — |
| CORRESP | Letter to the SEC | Dec 13, 2017 | — |
| CORRESP | Letter to the SEC | Dec 11, 2017 | — |
| UPLOAD | Letter from the SEC | Dec 6, 2017 | — |
| CORRESP | Letter to the SEC | Dec 4, 2017 | — |
| UPLOAD | Letter from the SEC | Nov 30, 2017 | — |
| CORRESP | Letter to the SEC | Nov 17, 2017 | — |
| UPLOAD | Letter from the SEC | Nov 14, 2017 | — |
| CORRESP | Letter to the SEC | Nov 1, 2017 | — |
| UPLOAD | Letter from the SEC | Oct 23, 2017 | — |
| D/A | Filing | Dec 30, 2016 | — |
| D | Filing | Dec 22, 2016 | — |
| D | Filing | Jun 19, 2015 | — |
| D | Filing | Jun 19, 2015 | — |
Showing 51 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CUE (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Somerville, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1645460
- Former names
- Imagen Biopharma, Inc. (until Jun 19, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.